SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Rogiers S)
 

Sökning: WFRF:(Rogiers S) > (2020-2024) > Understanding quali...

  • Egeler, M.D.Netherlands Cancer Institute, Amsterdam, Netherlands (författare)

Understanding quality of life issues in patients with advanced melanoma : Phase 1 and 2 in the development of the EORTC advanced melanoma module

  • Artikel/kapitelEngelska2024

Förlag, utgivningsår, omfång ...

  • Elsevier,2024
  • printrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:umu-226730
  • https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-226730URI
  • https://doi.org/10.1016/j.ejca.2024.114176DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Aims: We aimed to develop a European Organization for Research and Treatment of Cancer (EORTC) Quality of Life (QoL) module tailored for patients with advanced (resectable or unresectable stage III/IV) melanoma receiving immune checkpoint inhibitors or targeted therapy.Methods: Following the EORTC QoL Group module development guidelines, we conducted phases 1 and 2 of the development process. In phase 1, we generated a list of health-related (HR)QoL issues through a systematic literature review and semi-structured interviews with healthcare professionals (HCPs) and patients with advanced melanoma. In phase 2, these issues were converted into questionnaire items to create the preliminary module.Results: Phase 1: we retrieved 8006 articles for the literature review, of which 35 were deemed relevant, resulting in 84 HRQoL issues being extracted to create the initial issue list. Semi-structured interviews with 18 HCPs and 28 patients with advanced melanoma resulted in 28 issues being added to the initial issue list. Following EORTC module development criteria, 26 issues were removed, and two issues were added after review by patient advocates.Phase 2: To ensure uniformity and avoid duplication, 16 issues were consolidated into eight items. Additionally, an independent expert contributed one new item, resulting in a preliminary module comprising 80 HRQoL items.Conclusion: We identified a range of HRQoL issues (dry skin, xerostomia, and arthralgia) relevant to patients with stage III/IV melanoma. Future module development phases will refine the questionnaire. Once completed, this module will enable standardized assessment of HRQoL in patients with (locally) advanced melanoma.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • van Leeuwen, M.Netherlands Cancer Institute, Amsterdam, Netherlands (författare)
  • Lai-Kwon, J.Department of Medical Oncology and Department of Health Services Research, Peter MacCallum Cancer Centre, Melbourne, Australia (författare)
  • Eriksson, H.Theme Cancer, Karolinska University Hospital, Stockholm, Sweden; Department of Oncology-Pathology, Karolinska Institutet, Sweden (författare)
  • Bartula, I.Melanoma Institute Australia, The University of Sydney, Sydney, Australia (författare)
  • Elashwah, S.Medical Oncology Unit, Oncology Center, Mansoura University (OCMU), Egypt (författare)
  • Fox, L.King's College London, London, United Kingdom (författare)
  • Van Hemelrijck, M.King's College London, London, United Kingdom (författare)
  • Jefford, M.Department of Medical Oncology and Department of Health Services Research, Peter MacCallum Cancer Centre, Melbourne, Australia (författare)
  • Lijnsvelt, J.Netherlands Cancer Institute, Department of Medical Oncology, Amsterdam, Netherlands (författare)
  • Bagge, A.-S. LindqvistSahlgrenska Center for Cancer Research, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Department of Psychology, University of Gothenburg, Gothenburg, Sweden (författare)
  • Morag, O.Sheba Medical Center, The Jusjdman Cancer Center, Ramat-gan, Israel (författare)
  • Ny, L.Sahlgrenska Center for Cancer Research, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden (författare)
  • Bagge, R. OlofssonSahlgrenska Center for Cancer Research, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden (författare)
  • Rogiers, A.Department of Medical Oncology, Vrije Universiteit Brussel, Universitair Ziekenhuis Brussel, Brussels, Belgium (författare)
  • Saw, R.P.M.Melanoma Institute Australia, The University of Sydney, Sydney, Australia; Faculty of Medicine and Health, The University of Sydney, NSW, Sydney, Australia; Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, NSW, Sydney, Australia (författare)
  • Serpentini, S.Veneto Institute of Oncology, Veneto, Italy (författare)
  • Iannopollo, L.Veneto Institute of Oncology, Veneto, Italy (författare)
  • Thompson, J.Melanoma Institute Australia, The University of Sydney, Sydney, Australia (författare)
  • Tufvesson Stiller, HelenaUmeå universitet,Institutionen för folkhälsa och klinisk medicin(Swepub:umu)hetu0009 (författare)
  • Vanlaer, N.Sheba Medical Center, The Jusjdman Cancer Center, Ramat-gan, Israel (författare)
  • van Akkooi, A.C.J.Melanoma Institute Australia, The University of Sydney, Sydney, Australia; Faculty of Medicine and Health, The University of Sydney, NSW, Sydney, Australia; Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, NSW, Sydney, Australia (författare)
  • van de Poll-Franse, L.V.Netherlands Cancer Institute, Amsterdam, Netherlands (författare)
  • Netherlands Cancer Institute, Amsterdam, NetherlandsDepartment of Medical Oncology and Department of Health Services Research, Peter MacCallum Cancer Centre, Melbourne, Australia (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:European Journal of Cancer: Elsevier2070959-80491879-0852

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy